Comparative Pharmacology
Head-to-head clinical analysis: DESIPRAMINE HYDROCHLORIDE versus JANIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESIPRAMINE HYDROCHLORIDE versus JANIMINE.
DESIPRAMINE HYDROCHLORIDE vs JANIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Oral: Initial 25-75 mg/day in divided doses; increase gradually to 100-200 mg/day, maximum 300 mg/day. Usual maintenance: 100-200 mg/day single or divided doses.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
None Documented
None Documented
Terminal half-life 12–30 hours (mean ~22 hours); extensive interindividual variability due to CYP2D6 polymorphism.
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Renal excretion of metabolites accounts for approximately 70%; fecal elimination ~30%. Unchanged drug <5% in urine.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant